The Myeloma Trial Finder lists clinical trials which are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
It provides information about clinical trials in the UK. Trials included are not necessarily endorsed by Myeloma UK.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332
Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.
There are currently 24 open trials.
In 126 locations
What is a Clinical Trial?
There are currently 24 open trials
- Improving the early detection of myeloma in smouldering myeloma patients (COSMOS)
- CAEL-101 in AL amyloidosis patients (Mayo stage IIIa)
- CAEL-101 in AL amyloidosis patients (Mayo stage IIIb)
- Teclistamab for relapsed and refractory myeloma
- JNJ-68284528 CART-cell therapy for relapsed and refractory myeloma
- Belantamab mafodotin with bortezomib, lenalidomide and dexamethasone for newly diagnosed myeloma (DREAMM 9)
- Adaptive treatment in newly diagnosed myeloma patients not eligible for HDT-SCT (FiTNEss, Myeloma XIV)
- Evaluating patient-based treatment strategies for newly diagnosed myeloma patients (RADAR)
- Belantamab mafodotin in combination with bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-7)
- Belantamab mafodotin versus pomalidomide and dexamethasone for treatment of relapsed and/or refractory myeloma (DREAMM-3)
- A clinical trial evaluating RO5126766 for the treatment of refractory myeloma patients
- Understanding bone pain in myeloma
- Belantamab mafodotin (GSK2857916) combinations for treatment of relapsed/refractory myeloma (DREAMM-6)
- CCS1477 for the treatment of relapsed/refractory myeloma patients
- Oxford pre-cancerous disorders study (OxPLoreD)
- A study evaluating S65487 for the treatment of relapsed/refractory myeloma patients
- bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
- Venetoclax and dexamethasone in patients with relapsed or refractory myeloma (CANOVA)
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- CC-92480 for relapsed and refractory multiple myeloma
- AZD4573 in relapsed or refractory myeloma
- Observational evaluation of myeloma patients (PREAMBLE)
- CC-220 (iberdomide) as a monotherapy and in combination with other treatments
- Myeloma XII (ACCoRd)
Trial Title:
Improving the early detection of myeloma in smouldering myeloma patients (COSMOS)
Treatments:
Observation
Myeloma stage:
Smouldering
Trial phase:
Summary:
A study looking at how and why smouldering myeloma progresses to active myeloma.
Locations:
University College Hospital, London
Who can enter the study?:
Smouldering myeloma patients who have been diagnosed for less than five years.
What's involved?:
This is an observational study therefore no drugs are being tested.
Patients who join the study will be monitored and followed up as normal by their healthcare team. Samples from routine blood or bone marrow tests will be shared with the study team.
The study team will use the samples to measure the number and type of genetic changes in the abnormal plasma cells responsible for smouldering myeloma and the number and function of the immune cells in blood and bone marrow.
For more information contact the research team or visit the study website.
Clinical Information
(for Medical Professionals):
A UK wide observational study for smouldering myeloma patients to identify genetic and immune changes associated with progression to active myeloma. For more information contact the research team or visit the study website.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk